Hims & Hers Health (HIMS) News Today

Hims & Hers Health, Inc. (NYSE:HIMS) shares are trading lower today, pressured by recent insider selling and spillover volatility in the medical sector—even as strong fundamentals and bullish technicals point to further upside.

• Insider selling: CFO Oluyemi Okupe sold 11,581 shares at an average of $60.22, and CEO Andrew Dudum offloaded 128,127 shares at $58.40, prompting a roughly 2% pullback as investors digest the executives’ reduced ownership.
• Sector jitters: A 30% slump in UnitedHealth (UNH) briefly rattled medical stocks, though HIMS has held up better—trading around 85% of its 52-week high—thanks to distinct growth drivers.
• Technical breakout potential: The stock has formed a “three white soldiers” bullish continuation pattern, with rising support and converging volume and momentum indicators suggesting a retest of the $73 all-time high and a shot at $100 later in the year.
• Fundamental strength: Q1 revenue jumped 110% year-over-year to $586 million, EPS beat estimates, and subscribers grew 38%. Free cash flow is stabilizing and the balance sheet shows liabilities under 0.5× assets.
• Short-squeeze catalyst: Short interest hovered near 28% at the end of April. Combined with a 70% institutional ownership base, this sets the stage for a squeeze-driven rally if bearish positions cover.
• Institutional moves: Northern Trust raised its stake by 19.5%, signaling confidence, while Vanguard trimmed its position by 8.8%—likely a rebalancing move after HIMS’s 120% run over the past month.

In sum, while insider sales and sector‐wide volatility are weighing on HIMS today, robust earnings growth, a healthy balance sheet and bullish chart patterns underpin a favorable outlook heading into the Q2 results.